Severity
Critical
FDA Drug recall · Reported June 21, 2017
Non-sterility: presence of mold confirmed by outside laboratory at the 14 day culture.
Complete Pharmacy and Medical Solutions LLC recalled Human Chorionic Gonadotropin, 125 IU HCG, in 0.5 ml syringe, subcutaneous administration,… - a critical-severity action.
Human Chorionic Gonadotropin, 125 IU HCG, in 0.5 ml syringe, subcutaneous administration,… was recalled by Complete Pharmacy and Medical Solutions LLC in June 21, 2017. Reason: Non-sterility: presence of mold confirmed by outside laboratory at the 14 day culture.. Check the official notice for the remedy. Verify recall #D-0917-2017 with the FDA Drug before acting.
The recall
Complete Pharmacy and Medical Solutions LLC issued this critical-severity FDA Drug recall-Non-sterility: presence of mold confirmed by outside laboratory at the 14 day culture..
Sourced from official FDA Drug enforcement records. Verify recall #D-0917-2017 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0917-2017) was formally reported on June 21, 2017, with the manufacturer initiating the action on December 29, 2015. It is classified under Critical severity (Class I), with a current status of Ongoing. Complete Pharmacy and Medical Solutions LLC is listed as the recalling firm, operating out of Miami Lakes, FL. Federal records list the affected scope as 1890 syringes.
The documented reason for this recall is: Non-sterility: presence of mold confirmed by outside laboratory at the 14 day culture. Distribution data in the federal record shows the product reached: Distributed throughout Florida. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 40,322 medical devices recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified high severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Critical
Affected scope
1890 syringes
Related Recalls
6
0 from same agency
Human Chorionic Gonadotropin, 125 IU HCG, in 0.5 ml syringe, subcutaneous administration, Rx only, Complete Pharmacy & Medical Solutions, Miami Lakes, FL 33014
Non-sterility: presence of mold confirmed by outside laboratory at the 14 day culture.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Critical (Class I) |
| Status | Ongoing |
| Recall number | D-0917-2017 |
| Date reported | June 21, 2017 |
| Date initiated | December 29, 2015 |
| Recalling firm | Complete Pharmacy and Medical Solutions LLC |
| Firm location | Miami Lakes, FL |
| Affected scope | 1890 syringes |
| Distribution | Distributed throughout Florida |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
· 2026-07-02
· 2026-06-25
· 2026-06-18
GE Medical Systems Information Technologies Inc · 2026-06-03
Medline Industries, LP · 2026-06-03
Compare this recall with Rowenta Recalls Cordless Vacuum Cleaners Due to Risk of Ser… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported June 21, 2017. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.